Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Rui Jin,Boxuan Liu,Xiuju Liu,Yijian Fan,Wei Peng,Chunzi Huang,Adam Marcus,Gabriel Sica,Melissa Gilbert-Ross,Yuan Liu,Wei Zhou

DOI: https://doi.org/10.1158/1535-7163.22520611

2023-01-01

Abstract:Supplemental Figures and Tables

What problem does this paper attempt to address?

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Jin Zhang,Enshun Xu,Cong Ren,Hee Jung Yang,Yanhong Zhang,Wenqiang Sun,Xiangmudong Kong,Weici Zhang,Mingyi Chen,Eric Huang,Xinbin Chen

DOI: https://doi.org/10.1158/0008-5472.22417952

2023-01-01

Abstract:Supplemental Fig. S1 represents analysis of TLBL. Supplemental Fig. S2 contains representative images of H.E.-stained tumors. Supplemental Fig. S3 contains RT-PCR analysis of various genes (Tbet, NFAT1,NFAT2, IFNG, IL6) in thymus and TLBLs. Supplemental table S1-4 contains gender, survival, and tumor information of the mice.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.

Yicheng Chen,Qiaoli Huang,Hua Zhou,Yueping Wang,Xian Hu,Tao Li

DOI: https://doi.org/10.18632/oncotarget.10409

2016-01-01

Oncotarget

Abstract:Leflunomide (LEF), an inhibitor of dihydroorotate dehydrogenase (DHODH) in pyrimidine biosynthetic pathway, is an immunomodulatory agent approved for the treatment of rheumatoid arthritis. In this study, we show that LEF significantly reduced cell proliferation of renal carcinoma cells in a concentration-dependent manner. LEF at 50 mu M induced S-phase arrest and autophagy. Higher doses of LEF (>50 mu M) effectively induced cell apoptosis. Modulating the concentration of LEF resulted in distinct effects on the expression of regulatory proteins associated with cell cycle, apoptosis, and autophagy. In particular, high concentrations of LEF inhibited canonical WNT signaling by promoting nucleo-cytoplasmic shuttling and proteasome-dependent degradation of beta-catenin. Mechanistic studies showed that the repression of AKT activation partly accounted for LEF-mediated WNT inhibition. Gene expression microarray revealed that LEF treatment greatly inhibited the expression of FZD10 gene, a receptor mediating WNT/beta-catenin activation. In vivo xenograft study in NOD/SCID mice further validated the inhibitory effects of LEF on tumor growth and Wnt/beta-catenin signaling. However, LEF treatment also triggered cell autophagy and elevated the expression of WNT3a, which ameliorated its cytotoxic effects. The combination of LEF with a WNT inhibitor IWP-2 or autophagy inhibitor HCQ could yield an enhanced anti-tumor outcome. Taken together, these results identify the potential utility and pharmacological feature of LEF in the chemotherapy of renal cell carcinoma (RCC).
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422753

2023-01-01

Abstract:Supplementary Methods for Xie et al, MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer
Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Rui-Yan Wu,Peng-Fei Kong,Liang-Ping Xia,Yun Huang,Zhi-Ling Li,Yun-Yun Tang,Yu-Hong Chen,Xuan Li,Ravichandran Senthilkumar,Hai-Liang Zhang,Ting Sun,Xue-Lian Xu,Yan Yu,Jia Mai,Xiao-Dan Peng,Dong Yang,Li-Huan Zhou,Gong-Kan Feng,Rong Deng,Xiao-Feng Zhu

DOI: https://doi.org/10.1158/1078-0432.22471275.v1

2023-01-01

Abstract:Supplementary Figures + Supplementary Datas
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Table 4 from Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Yunlu Jia,Jianbiao Zhou,Tze King Tan,Tae-Hoon Chung,Yongxia Chen,Jing-Yuan Chooi,Takaomi Sanda,Melissa J. Fullwood,Sinan Xiong,Sabrina H.M. Toh,Kalpnaa Balan,Regina W.J. Wong,Julia S.L. Lim,Enfan Zhang,Zhen Cai,Peng Shen,Wee Joo Chng

DOI: https://doi.org/10.1158/0008-5472.22582472

2023-01-01

Abstract:Supplementary Table 4 shows the sequences of SE fragments inserted into pGL3 vector
Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung

Jiankang Zhang,Jingxiao Chen,Wang Da,Hongyuan Yan,Peng Liu,Evan Ma,Limei Li,Lirong Zheng,Daxin Chen,Zuoren Yu,Chao Liang,Jun Peng,Dan‐ni Ren,Weidong Zhu

DOI: https://doi.org/10.1158/1078-0432.22471844.v1

2023-01-01

Abstract:Supplementary Figures, Figure legends and Tables
Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.
Supplementary Data from the Hepatic Microenvironment Uniquely Protects Leukemia Cells Through Induction of Growth and Survival Pathways Mediated by LIPG

Haobin Ye,Mohammad Minhajuddin,Anna Krug,Shanshan Pei,Chih-Hsing Chou,Rachel Culp‐Hill,Jessica Ponder,Erik De Bloois,Björn Schniedewind,M.F. Amaya,Anagha Inguva,Brett M. Stevens,Daniel A. Pollyea,Uwe Christians,H. Leighton Grimes,Angelo D’Alessandro,Craig T. Jordan

DOI: https://doi.org/10.1158/2159-8290.22536566

2023-01-01

Abstract:Supplementary figures and information
Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with <i>vhl</i> Loss

Lianxin Hu,Haibiao Xie,Xijuan Liu,Frances Potjewyd,Lindsey I. James,Emily M. Wilkerson,Laura E. Herring,Lihua Xie,Xian Chen,Johnny Castillo Cabrera,Kai Hong,Chengheng Liao,Xianming Tan,Albert S. Baldwin,Kan Gong,Qing Zhang

DOI: https://doi.org/10.1158/2159-8290.22535705.v1

2023-01-01

Abstract:Extended methods and supplementary figures
Supplementary Figure 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xing,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xiaoze Du,Tang Li,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399941

2023-01-01

Abstract:PDF file - 150KB, Supplementary Figure 4 Validation of the specificity of anti-LSECtin.
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
Supplementary Figure 7 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xing,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xiaoze Du,Tang Li,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399932.v1

2023-01-01

Abstract:PDF file - 78KB, Supplementary Figure 7 Confirmation of LAG-3 expression on T cells.
Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Yongxian Hu,Zhao Wu,Yi Luo,Jimin Shi,Jian Yu,Chengfei Pu,Zuyu Liang,Guoqing Wei,Qu Cui,Jie Sun,Jing Jiang,Jue Xie,Yamin Tan,Wanmao Ni,Jifang Tu,Jinping Wang,Aiyun Jin,Hao Zhang,Zhen Cai,Lei Xiao,He Huang

DOI: https://doi.org/10.1158/1078-0432.22462346.v1

2023-01-01

Abstract:The cumulative incidence of non-relapse mortality are shown.
Supplementary Figures and Table from Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers

Xinxin Song,Zhuan Zhou,Hongchun Li,Yifan Xue,Xinghua Lu,Ivet Bahar,Oliver Kepp,Mien-Chie Hung,Guido Kroemer,Yong Wan

DOI: https://doi.org/10.1158/2159-8290.22535741.v1

2023-01-01

Abstract:Supplementary Figures 1-8 Supplementary Table 1
Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Yuqin Song,Zhengming Jin,Zhi-Ming Li,Yanyan Liu,Lanfang Li,Chuan He,Hang Su,Hui Zhou,Kunyan Li,Siguo Hao,Xuelan Zuo,Jianyuan Wu,Dengju Li,Meng Wu,Xiuhua Sun,Junyuan Qi,Zhen Cai,Zengjun Li,Yijing Li,Yanhua Huang,Jie Shen,Zhenyu Xiao,Jun Zhu

DOI: https://doi.org/10.1158/1078-0432.25515657

2024-01-01

Abstract:Supplementary Figure S1. Progression-free survival by lymphoma subtype.

Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplementary Table 4 from Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Data from the Hepatic Microenvironment Uniquely Protects Leukemia Cells Through Induction of Growth and Survival Pathways Mediated by LIPG

Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with &lt;i&gt;vhl&lt;/i&gt; Loss

Supplementary Figure 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Figure 7 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Supplementary Figures and Table from Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers

Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with <i>vhl</i> Loss